報價延遲最少15分鐘:2025/06/05 19:34 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
15.91 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.81/-3.53
|
|
企業價值
906.32M
|
| 資產負債 |
|
每股賬面淨值
4.69
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/05 19:34 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel smallmolecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. |